Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹20,886 Cr
Revenue (TTM)
₹2,177 Cr
Net Profit (TTM)
₹201 Cr
ROE
15.7 %
ROCE
21.3 %
P/E Ratio
104
P/B Ratio
25.1
Industry P/E
28.7
EV/EBITDA
62.8
Div. Yield
0.4 %
Debt to Equity
0
Book Value
₹332.6
EPS
₹83.3
Face value
2
Shares outstanding
25,000,000
CFO
₹603.38 Cr
EBITDA
₹1,116.84 Cr
Net Profit
₹709.32 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Astrazeneca Pharma
| -7.3 | -5.8 | -7.8 | 5.8 | 35.5 | 21.3 | 21.8 |
|
BSE Healthcare
| -4.0 | -3.8 | -4.0 | 3.0 | 24.6 | 15.5 | 10.6 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Astrazeneca Pharma
| 25.5 | 29.4 | 67.6 | 6.4 | -33.1 | 76.4 | 81.3 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Astrazeneca Pharma
|
8,370.5 | 20,886.1 | 2,177.5 | 200.9 | 11.3 | 26.5 | 104 | 25.1 |
| 2,943.9 | 36,807.9 | 5,201.6 | 1,014.6 | 22.9 | 25 | 36.3 | 8.0 | |
| 1,621.8 | 12,325.3 | 2,089.5 | 622.0 | 31.3 | 20.4 | 20.1 | 3.7 | |
| 1,286.2 | 17,770.9 | 3,078.2 | 469.4 | 26.4 | 14.9 | 41.2 | 4.9 | |
| 2,084.9 | 33,478.1 | 4,193.0 | 753.8 | 22.7 | 20.8 | 44.4 | 8.4 | |
| 4,724.5 | 21,607.1 | 2,482.3 | 853.6 | 33.7 | 18.9 | 25.3 | 5.4 | |
| 4,819.4 | 8,003.6 | 1,348.5 | 293.5 | 28.1 | 50.7 | 27.3 | 11.5 | |
| 3,408.1 | 7,850.1 | 1,837.4 | 326.7 | 24.7 | 45.3 | 24 | 10.5 | |
| 314.8 | 6,154.0 | 1,432.0 | 149.0 | 19.1 | 7.9 | 41 | 2.5 | |
| 897.6 | 8,271.1 | 4,725.6 | 528.7 | 14.9 | 20.7 | 16.2 | 2.8 |
No Review & Analysis are available.
AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, markets, and trades in pharmaceutical products in India and internationally. It provides medicines for cardiovascular, renal, metabolic, and immunological conditions;... oncology medicines under the TAGRISSO, Lynparza, ENHERTU, IMFINZI, and Zoladex brand names; rare diseases medicines under the Koselugo brand name; and respiratory medicines under the Symbicort and Fasenra brand names. The company also offers medicines for diabetes; and clinical trial services. The company was incorporated in 1979 and is based in Bengaluru, India. AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca Pharmaceuticals AB. Read more
Incorporated
1979
Chairman
Shilpa Divekar Nirula
Managing Director
--
Group
Astrazeneca Pharma India - MNC
Headquarters
Bengaluru, Karnataka
Website
Looking for more details about Astrazeneca Pharma India Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
The share price of Astrazeneca Pharma India Ltd is ₹8,370.50 (NSE) and ₹8,354.45 (BSE) as of 19-Mar-2026 IST. Astrazeneca Pharma India Ltd has given a return of 35.49% in the last 3 years.
The P/E ratio of Astrazeneca Pharma India Ltd is 103.97 times as on 19-Mar-2026, a 262 premium to its peers’ median range of 28.70 times.
The P/B ratio of Astrazeneca Pharma India Ltd is 25.12 times as on 19-Mar-2026, a 450 premium to its peers’ median range of 4.57 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
185.90
|
28.19
|
|
2024
|
82.35
|
18.77
|
|
2023
|
81.76
|
13.85
|
|
2022
|
103.71
|
12.54
|
|
2021
|
80.66
|
16.55
|
The 52-week high and low of Astrazeneca Pharma India Ltd are Rs 10,691.00 and Rs 7,201.15 as of 20-Mar-2026.
Astrazeneca Pharma India Ltd has a market capitalisation of ₹ 20,886 Cr as on 19-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Astrazeneca Pharma India Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹-113.00
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.